Establishment of neurofilament light chain Simoa assay in cerebrospinal fluid and blood

被引：85
作者：
Hendricks, Robert [1 ]
Baker, Dana [1 ]
Brumm, Jochen [2 ]
Davancaze, Teresa [1 ]
Harp, Chris [3 ]
Herman, Ann [3 ]
von Budingen, H-Christian [4 ]
Townsend, Michael [5 ]
Fischer, Saloumeh K. [1 ]
机构：
[1] Genentech Inc, Dept BioAnalyt Sci, San Francisco, CA 94080 USA
[2] Genentech Inc, Dept Biostat, San Francisco, CA 94080 USA
[3] Genentech Inc, OMNI Biomarker Dev, San Francisco, CA 94080 USA
[4] Roche, Neurosci, Prod Dev, Basel, Switzerland
[5] Genentech Inc, Biomarker Discovery OMNI, San Francisco, CA 94080 USA
来源：
BIOANALYSIS | 2019年 / 11卷 / 15期
关键词：
Alzheimer's disease (AD); amyotrophic lateral sclerosis (ALS); biomarker; cerebrospinal fluid (CSF); multiple sclerosis (MS); neurodegeneration; neurofilament light (NfL) chain; Quanterix Simoa (TM); UmanDiagnostics Nf-Light ELISA (Uman ELISA); QUANTIFICATION; BIOMARKER; SERUM;
D O I：
10.4155/bio-2019-0163
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
Background: Neurofilament light (NfL) chain is an established cerebrospinal fluid (CSF) biomarker for neuroaxonal injury. The highly sensitive Quanterix SimoaT platform is evaluated for NfLmeasurement in both CSF and blood. There is a need to link historical ELISA data that use bovine NfL to that of Simoa using a recombinant human (rhuman) NfL standard. Results/Methodology: The Simoa NF-light (R) Advantage Kit was validated for CSF and qualified for serum and plasma, using both rhuman and bovine NfL calibrators. Matched CSF, serum and plasma samples from 112 multiple sclerosis patients were analyzed using both calibrators. Conclusion: In multiple sclerosis, there is a good correlation between blood and CSF NfL levels. A conversion factor of approximately 5:1 was established between bovine and rhuman NfL calibrators.
引用
收藏
页码：1405 / 1418
页数：14
相关论文
共 15 条
  • [1] Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases
    Bacioglu, Mehtap
    Maia, Luis F.
    Preische, Oliver
    Schelle, Juliane
    Apel, Anja
    Kaeser, Stephan A.
    Schweighauser, Manuel
    Eninger, Timo
    Lambert, Marius
    Pilotto, Andrea
    Shimshek, Derya R.
    Neumann, Ulf
    Kahle, Philipp J.
    Staufenbiel, Matthias
    Neumann, Manuela
    Maetzler, Walter
    Kuhle, Jens
    Jucker, Mathias
    [J]. NEURON, 2016, 91 (01) : 56 - 66
  • [2] Serum Neurofilament Light: A Biomarker of Neuronal Damage in Multiple Sclerosis
    Disanto, Giulio
    Barro, Christian
    Benkert, Pascal
    Naegelin, Yvonne
    Schadelin, Sabine
    Giardiello, Antonella
    Zecca, Chiara
    Blennow, Kaj
    Zetterberg, Henrik
    Leppert, David
    Kappos, Ludwig
    Gobbi, Claudio
    Kuhle, Jens
    [J]. ANNALS OF NEUROLOGY, 2017, 81 (06) : 857 - 870
  • [3] Neurofilament light chain as a biomarker in neurological disorders
    Gaetani, Lorenzo
    Blennow, Kaj
    Calabresi, Paolo
    Di Filippo, Massimiliano
    Parnetti, Lucilla
    Zetterberg, Henrik
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2019, 90 (08) : 870 - 881
  • [4] Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases
    Gaiottino, Johanna
    Norgren, Niklas
    Dobson, Ruth
    Topping, Joanne
    Nissim, Ahuva
    Malaspina, Andrea
    Bestwick, Jonathan P.
    Monsch, Andreas U.
    Regeniter, Axel
    Lindberg, Raija L.
    Kappos, Ludwig
    Leppert, David
    Petzold, Axel
    Giovannoni, Gavin
    Kuhle, Jens
    [J]. PLOS ONE, 2013, 8 (09):
  • [5] Neurofilament Light in Serum and Cerebrospinal Fluid of Hip Fracture Patients with Delirium
    Halaas, Nathalie Bodd
    Blennow, Kaj
    Idland, Ane-Victoria
    Wyller, Torgeir Bruun
    Raeder, Johan
    Frihagen, Frede
    Staff, Anne Cathrine
    Zetterberg, Henrik
    Watne, Leiv Otto
    [J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2018, 46 (5-6) : 346 - 357
  • [6] Recommendations for adaptation and validation of commercial kits for biomarker quantification in drug development
    Khan, Masood U.
    Bowsher, Ronald R.
    Cameron, Mark
    Devanarayan, Viswanath
    Keller, Steve
    King, Lindsay
    Lee, Jean
    Morimoto, Alyssa
    Rhyne, Paul
    Stephen, Laurie
    Wu, Yuling
    Wyant, Timothy
    Lachno, D. Richard
    [J]. BIOANALYSIS, 2015, 7 (02) : 229 - 242
  • [7] Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
    Kuhle, Jens
    Kropshofer, Harald
    Haering, Dieter A.
    Kundu, Uma
    Meinert, Rolf
    Barro, Christian
    Dahlke, Frank
    Tomic, Davorka
    Leppert, David
    Kappos, Ludwig
    [J]. NEUROLOGY, 2019, 92 (10) : E1007 - E1015
  • [8] Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity
    Kuhle, Jens
    Barro, Christian
    Disanto, Giulio
    Mathias, Amandine
    Soneson, Charlotte
    Bonnier, Guillaume
    Yaldizli, Oezguer
    Regeniter, Axel
    Derfuss, Tobias
    Canales, Mathieu
    Schluep, Myriam
    Du Pasquier, Renaud
    Krueger, Gunnar
    Granziera, Cristina
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (12) : 1550 - 1559
  • [9] Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa
    Kuhle, Jens
    Barro, Christian
    Andreasson, Ulf
    Derfuss, Tobias
    Lindberg, Raija
    Sandelius, Asa
    Liman, Victor
    Norgren, Niklas
    Blennow, Kaj
    Zetterberg, Henrik
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2016, 54 (10) : 1655 - 1661
  • [10] Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease
    Lin, Yung-Shuan
    Lee, Wei-Ju
    Wang, Shuu-Jiun
    Fuh, Jong-Ling
    [J]. SCIENTIFIC REPORTS, 2018, 8
12